Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma -- sBLA Filing Based on Landmark ZUMA-7 Study, the ...

Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel). The application seeks to expand Yescarta ...

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA ...

Amgen (NASDAQ: AMGN) and Kite Pharma (NASDAQ: KITE) announced today that the two companies have entered into a strategic research collaboration and license agreement to develop and commercialize the ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric ...

Online brokerage firm Zerodha has clarified why Kite users received the OTPs while logging into its Kite application. Users of the Kite app were asked to share OTPs before logging into the app. For ...

Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates Amgen Eligible to Receive up to $525 Million in Milestone Payments per ...

-- Filing for Kite’s Second CAR T Cell Therapy Marks Potential Expansion of Company’s Cell Therapy Portfolio -- Santa Monica, Calif., 28 January, 2020 – Kite, a Gilead Company (Nasdaq: GILD), today ...